Jordana Fein, MD 

1:25- Rationale for high dose aflibercept

22:29- Faricimab and role of ang-2 inhibition

Videos

Ehsan Rahimy, MD; David G. Miller, MD, and Jordana Fein, MD, discusses how 8 milligram aflibercept and faricimab, newer anti-VEGF therapies for retinal diseases, offer improved durability with comparable safety profiles to existing treatments, allowing less frequent injections while maintaining equivalent vision outcomes.

Jordana Fein, MD

Articles